AB-Pred by Biogenity AB-Pred is an early-stage software developed to combine the science of Protein Chemistry and Artificial Intelligence in a mission to reduce the development time and cost of new recombinant antibodies. The development was made possible by an international collaboration between Biogenity and one of the world-leading providers of contract research within the development of recombinant antibodies using Phage Display. An introduction to Biogenity Founded in 2018, Biogenity is a data-driven biotechnology company focused on transforming biological data into valuable knowledge for the industry. The company has a fee-for-service consultancy, which can be divided into CRO service within Omics studies, and Deep Learning modelling of biological data. Proteomics Core Facility: In august 2020, we launched our first full service, the Proteomics Core Facility. Our team is highly qualified and we are offering a complete solution from sample to biology. Today, we are serving international big pharma companies, academia, and biotech companies all around the world. https://biogenity.com/proteomics-core-facility Horizon 2020: At Biogenity, we are very excited to be a part of EXIMIOUS_H2020. The €10 Mio research project aims to develop a new way of assessing the human exposome, to better understand the factors that lead to exposure-related autoimmune effects at different stages of people's lives. Biogenity's role is to test the hypothesis that neural networks can identify new connections between autoimmune diseases and the work environment using health data and JEMs. The Biogenity team Biogenity consists of two founders with a fantastic team of PhDs. We excel at being an interdisciplinary team consisting of domain experts, data scientists, and commercialization. Some of our amazing achievements Grants and accelerators: Since the founding days of Biogenity, we have been privileged to participate in several programs, including Innovativ Vækst, Innofounder Graduate, Accelerace's Beyond Beta. Biogenity has also being granted Innovation Fund Denmark's Innobooster Grant and is a key partner in Horizon 2020: Eximious. Awards and nominations: This year, we were nominated for EY's "Entrepreneur of the Year" in the category "startup." In December 2019, we were awarded the "Entrepreneur of the Year"-award from Open Entrepreneurship and the Danish Industry Foundation in the category “Best spinout team”. Milestones: We have reached an incredible number of milestones in the last three years, but the three most significant have been getting our first product on the market, setting up our Proteomics Core Facility with DTU, and reaching the stage of beta testing with the first module of AB-Pred. To achieve all these milestones, we need to dedicate sincere gratitude towards our advisors, accelerators, funds, and other kind-hearted people who have helped us on our journey.